The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...
Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...
News-Medical.Net on MSN
Blood markers can indicate people at risk of developing ulcerative colitis
Researchers at örebro University have identified blood markers that can indicate who is at risk of developing ulcerative ...
Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients in the PRA023 group achieved clinical remission at 12 weeks vs. placebo (26.5% ...
More than a quarter of patients with ulcerative colitis do not receive prior advanced therapy before initiating mirikizumab, ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
Colitis Symptoms Ulcerative Colitis Symptoms How They Differ Treatment Options Colitis and ulcerative colitis (UC) can look very similar because they share symptoms like abdominal pain, diarrhea, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results